DGAP-News: CureVac / Key word(s): Research Update/Study results 
CureVac : Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants 
in Preclinical Study 
2021-05-13 / 13:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in 
Preclinical Study 
- Second-generation lead COVID-19 vaccine candidate, CV2CoV, developed in collaboration by CureVac and GSK 
- CV2CoV mRNA shows high levels of antigen production in rat model 
- Fast onset of strong neutralizing antibody titers after first vaccination 
- High cross-neutralizing capacity of induced antibodies against selected Variants of Concern 
TÜBINGEN, Germany/ BOSTON, USA - May 13, 2021 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company 
developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced together 
with its collaboration partner GSK, first preclinical data in a rat model, showing that its second-generation COVID-19 
vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune 
responses in vaccinated animals. CV2CoV is a co-development between CureVac and GSK and is based on a new mRNA 
backbone, which differs from CureVac's first-generation vaccine candidate, CVnCoV, currently in late-stage clinical 
testing. Preclinical data in rats immunized with CV2CoV in the dose range of 0.5-40µg demonstrated fast onset of strong 
immune responses already after the first dose. In addition, the serum of vaccinated animals showed significant 
cross-neutralization against variants first discovered in Denmark (B.1.1.298), the UK (B.1.1.7) and South Africa 
(B.1.351). The full manuscript of the preclinical data is available on the pre-print server bioRxiv. 
"mRNA technology has made tremendous progress since the clinical development of first-generation mRNA COVID-19 vaccine 
candidates started in early 2020, " said Dr. Igor Splawski, Chief Scientific Officer of CureVac. "Spurred by the 
emergence of virus variants that have the potential to affect the efficacy of currently approved first-generation mRNA 
COVID-19 vaccines, CureVac and GSK aim to jointly develop second-generation vaccine candidates that offer improved 
immune responses and target emerging variants. Combined with lower doses, these second-generation vaccines could enable 
also broad protection against selected strains in a multivalent vaccine format." 
Roger Connor, president R&D GSK vaccines said "to successfully fight the COVID-19 pandemic in the long term, we will 
need different vaccines and we need to be able to respond effectively to emerging variants. We are pleased with these 
pre-clinical results as they show the potential of the next generation mRNA technology we are developing together with 
CureVac." 
CV2CoV is based on a new mRNA backbone that features targeted optimizations designed to improve intracellular mRNA 
stability and translation for increased and extended protein expression. These optimizations potentially allow for 
strong immune responses at low doses, which will support the development of multivalent vaccines to target rapidly 
spreading COVID-19 variants. First clinical trials for CV2CoV are expected to start in the third quarter of 2021. 
Development of CV2CoV is carried out in collaboration with GSK. The CureVac-GSK COVID-19 collaboration announced in 
February 2021 extends the existing strategic mRNA technology partnership both companies entered in July 2020. The 
partnership targets second-generation vaccines and those with the potential for a multivalent or combination approach 
to address multiple emerging variants in one vaccine. 
About CVnCoV 
CureVac began development of its mRNA-based COVID-19 vaccine candidates in January 2020. The vaccine candidate chosen 
first for clinical development, CVnCoV, is an optimized, non-chemically modified mRNA, encoding the prefusion 
stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles (LNPs). Phase 1 
and 2a clinical trials of CVnCoV began in June and September 2020, respectively. Phase 1 interim data reported in 
November 2020 showed that CVnCoV was generally well tolerated across all tested doses and induced strong antibody 
responses in addition to first indication of T cell activation. The quality of immune response was comparable to 
recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection. In December 2020, 
CureVac initiated a pivotal Phase 2b/3, the HERALD study, with a 12µg dose of CVnCoV. In February 2021, CureVac 
initiated a rolling submission with the European Medicines Agency (EMA) for CVnCoV. 
About CureVac 
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years 
of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of 
CureVac's proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human 
body to produce its own proteins capable of fighting a broad range of diseases. Based on its proprietary technology, 
the Company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody 
therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 
2020. It is headquartered in Tübingen, Germany, and employs more than 600 people at its sites in Tübingen, Frankfurt, 
and Boston, USA. Further information can be found at www.curevac.com. 
About GSK 
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live 
longer. For further information please visit: www.gsk.com/en-gb/about-us/. 
CureVac Media Contact 
Anna Kamilli, Manager Communications 
CureVac, Tübingen, Germany 
T: +49 7071 9883-1684 
anna.kamilli@curevac.com 
CureVac Investor Relations Contact 
Dr. Sarah Fakih, Vice President Investor Relations 
CureVac, Tübingen, Germany 
T: +49 7071 9883-1298 
M: +49 160 90 496949 
sarah.fakih@curevac.com 
Forward-Looking Statements 
This press release contains statements that constitute "forward looking statements" as that term is defined in the 
United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, 
expectations, beliefs, plans, objectives, assumptions or projections of CureVac (the "company") regarding future events 
or future results, in contrast with statements that reflect historical facts. Examples include discussion of the 
potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, 
growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology 
such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," 
"could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking 
statements are based on management's current beliefs and assumptions and on information currently available to the 
company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not 
place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other 
variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the 
worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and 
clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and 
collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in 
current and proposed legislation, regulations and governmental policies, pressures from increasing competition and 
consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of 
operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability 
to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other 
factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place 
undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual 
results to differ materially from those it thought would occur. The forward-looking statements included in this press 
release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation 
to update any such statements or to publicly announce the results of any revisions to any such statements to reflect 
future events or developments, except as required by law. 
For further information, please reference the company's reports and documents filed with the U.S. Securities and 
Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov. 
=---------------------------------------------------------------------------------------------------------------------- 
2021-05-13 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      CureVac

(MORE TO FOLLOW) Dow Jones Newswires

May 13, 2021 07:31 ET (11:31 GMT)